Vycor Medical Inc
Vycor Medical Inc. is a U.S.-based medical device company focused on neurosurgical access systems and non-invasive vision rehabilitation therapies. Its business is organized around two operating units: Vycor Medical, which designs and markets the ViewSite Brain Access System for brain and spine procedures, and NovaVision, which offers computer-based therapy for patients with vision disorders caused by neurological injury.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaBrain and spine surgery access and retraction systems, including VBAS.
Computer-based therapies for patients with vision disorders after brain injury.
Asiakkaat
Vycor sells primarily to hospitals and surgical users that need specialized tools for neurosurgery, especially brain and spine procedures. NovaVision serves patients with neurological vision impairment through providers, distributors, and potential digital-health partners that can reach end users efficiently. The company also targets international markets where its products are cleared or distributed through local channels.
Buy VBAS and related neurosurgical tools for brain and spine procedures because they need specialized access systems.
Use the access and retraction systems in procedures where precision and minimally invasive access matter.
Use NovaVision therapies for vision loss caused by stroke or other brain injury.
Help commercialize NovaVision and expand international access to Vycor products.
Strategia
Vycor’s strategy centers on expanding revenue through deeper U.S. penetration, broader international distribution, and continued product development around its neurosurgical platform. The company also seeks to add complementary products and pursue partnerships or alternatives for NovaVision to extend reach without building a large direct sales force.
The domestic hospital market is the core commercial base for VBAS and related products.
International markets diversify revenue and can scale the neurosurgical platform beyond the U.S.
Partnerships can extend reach for a niche therapy platform without heavy direct commercialization spend.
Complementary products can increase wallet share and leverage the existing distribution network.
Maantiede
Q1/2026Vycor is headquartered in the United States and manufactures its products and raw materials domestically. Most sales are to U.S. hospitals, but the company also exports to Canada, Japan, the UK, and the EU, making international market access an important part of the business. Regulatory approvals such as FDA 510(k) clearance and CE Marking support sales across multiple regions.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
Vycor depends on a small number of specialized products and on hospital purchasing cycles, so adoption or reimbursement delays can affect growth. Its international business is exposed to regulatory approvals, trade tariffs, and channel execution, while NovaVision’s commercialization depends on finding effective partners or strategic alternatives. As a medical device company, it also faces product development, clinical adoption, and quality/regulatory risks that can slow market expansion.
A large share of the business is tied to one neurosurgical access system, so adoption changes can move revenue materially.
Kohdistuu: Neurosurgical device sales
NovaVision’s reach relies on third parties with direct access to end users or digital-health capability.
Kohdistuu: Distribution and licensing
Medical devices require ongoing certification, clearance, and quality-system compliance to sell and maintain market access.
The company exports to Canada, Japan, the UK and the EU, so retaliatory tariffs or trade friction could reduce international demand.
Kohdistuu: Export markets
Although products are manufactured in the U.S., raw material prices and supply availability can still be affected by global trade conditions.
Kohdistuu: Manufacturing inputs
Kirjanpito
Harkinnanvaraiset erätSmall shipment timing changes can materially affect quarterly revenue in a low-volume business.
Vaikutus: Reported sales and gross profit
Historic customer credits were written off in prior periods, showing that recoverability and adjustments can affect other income.
Vaikutus: Other income and net results
Residual wind-down costs from discontinued operations can continue even after revenue stops.
Vaikutus: Below-the-line operating results
Management must estimate amounts that are not directly observable, which can materially change reported figures.
Vaikutus: Assets, liabilities, revenue, and expenses
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
electroCore, Inc.
ECOR · Electromedical & Electrotherapeutic Apparatus
Vicor Corporation
VICR · Electronic Components, NEC
Vicor Corp designs and manufactures modular power components and power delivery systems used to convert and distribute electrical power in advanced electronic equipment.
Neuronetics, Inc.
STIM · Surgical & Medical Instruments & Apparatus
Stryker Corporation
SYK · Surgical & Medical Instruments & Apparatus
ClearPoint Neuro, Inc.
CLPT · Surgical & Medical Instruments & Apparatus
Medtronic plc
MDT · Electromedical & Electrotherapeutic Apparatus
Medtronic plc designs, manufactures, and sells medical technologies used to diagnose, treat, and manage chronic and acute conditions across the body.
Päivitetty: 24.9.2026